glp·helper
glphelper.com/mounjaro/california/covina
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Covina, CA

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Mounjaro is FDA-approved for type 2 diabetes, not for weight management.[1] The tirzepatide approved for chronic weight management is Zepbound in Covina.

Physicians near Covina, CA from the federal NPI registry. Ask each office whether it prescribes Mounjaro.[9]

city providers
26
as of today

Same molecule (tirzepatide): Tirzepatide in Covina, Zepbound in Covina

Other GLP-1 medicines: Ozempic in Covina, Wegovy in Covina, Semaglutide in Covina

§ 02Provider directory: California
26 of 26 shown

Find a Mounjaro provider in Covina.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Mounjaro by California town, physicians per town
§ 03Getting Mounjaro in Covina
26 providers · Covina, CA

How to get Mounjaro in Covina.

26 GLP-1 prescribers and 6 local resource types are on record for Covina, plus 3 nearby towns in the directory.

Physicians in Covina
26 physicians
26 physicians from the federal NPI registry in Covina, most listed as Family Medicine (12), Internal Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are West Covina (29 providers), Azusa (21 providers) and Glendora (23 providers).
Around the prescription in Covina
6 listed nearby
26 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 4 places to move are on record near Covina.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

Bar chart of Mounjaro dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Mounjaro comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (per dose)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Zepbound is the tirzepatide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Covina

Covina, California has a population of 51,268 people. The adult obesity rate in Covina is an age-adjusted estimate of 25.8%, 3.3 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 10.8% of adults in Covina. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 24.9% of adults in Covina.

of Covina adults have obesity
25.8%
diagnosed diabetes
10.8%
no regular physical activity
24.9%

Age-adjusted estimates for Covina, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Mounjaro in Covina
6 dietitians

The prescription is one part. Here is the rest, in Covina.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Covina, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Elizabeth Batalao
RD
Registered dietitian
17016 E Queenside Dr
Call 323-487-9466NPI 1891653481
Sharon Beckwith, RDN
RD
Registered dietitian
8876 Mission Blvd
Call 626-483-7384NPI 1427797018
Marilyn Briseno, R.D
RD
Registered dietitian
330 S Aldenville Ave
Call 626-232-1227NPI 1639445992
Kody Colman, RD
RD
Registered dietitian
535 S 2Nd Ave
Call 626-214-1480NPI 1588492102
Kelly Cornelius, RD
RD
Registered dietitian
449 W D St Ste B
Call 559-358-4828NPI 1164187589
Jacqueline De Los Reyes, RD, CLE
RD
Registered dietitian
16120 E Badillo St
Call 626-856-8811NPI 1790068708

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Fitness 19
GYM
4.9 on Google · 2,631 reviews
207 N Grand Ave
Website
Fitness 19
GYM
4.9 on Google · 2,077 reviews
1422 S Azusa Ave
Website
EōS Fitness
GYM
3.8 on Google · 747 reviews
502 Plaza Dr
Website
LA Fitness
GYM
4.1 on Google · 611 reviews
3101 E Garvey Ave N
Website
24 Hour Fitness
GYM
4.0 on Google · 592 reviews
1530 W Covina Pkwy
Website
Planet Fitness
GYM
4.2 on Google · 514 reviews
1480 N Azusa Ave Ste A
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Mounjaro side effects are stomach and gut effects.

In Mounjaro's diabetes trials at 5 to 15 mg, the most common side effects were nausea (12 to 18%), diarrhea (12 to 17%), decreased appetite (5 to 11%), and vomiting (5 to 9%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 18%
mild
Most reports came during dose escalation and decreased over time
Diarrhea
12 to 17%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
6 to 7%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Mounjaro costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Mounjaro monthly cost by how you pay
Pharmacy retail (no insurance)$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
LillyDirect self-payfrom $499per monthListed at the same starting price for every strength, 2.5 mg to 15 mg
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Medicare Part D$0 to $100per monthT2D covered; weight-loss indication not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Mounjaro providers in Covina

Physicians from the federal NPI registry. Ask each office whether it prescribes Mounjaro.

Mounjaro in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Mounjaro.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in California

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]